Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer

ConditionProstate CA

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexMale

Age18-80

SponsorFirst Affiliated Hospital of Fujian Medical University

About this trial

68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.

Eligibility criteria

Qualifiers

confirmed treated or untreated prostate cancer patients;

signed written consent.

Disqualifiers

known allergy against PSMA;

any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Trial design

Treatments tested in this trial

68Ga-PSMA-CYC
CYC

Treatment groups

40 Participants

are divided into 2 treatment groups

Sponsors and collaborators

First Affiliated Hospital of Fujian Medical University

Lead sponsor

Source ClinicalTrials.gov